Teva- Pharmaceutical Industries Ltd (TEVA) is overvalued and Zoetis Inc (ZTS) is undervalued.
Against our estimates of intrinsic value, ZTS trades at the wider discount: a margin of safety of +27%, against -110% for TEVA.
Values as of the 17 Nov 2026 close.
Discounting its cash flows at 9.7% (average of 3 methods) values the shares at $20.28; the price of $42.62 is 110% above that value, and 73% of that value comes from beyond year five.
Leak Score: free with an account
Discounting its cash flows at 8.1% (average of 3 methods) values the shares at $113.90; the price of $83.48 is 27% below that value, and 79% of that value comes from beyond year five.
Leak Score: free with an account
| Metric | TEVA | ZTS |
|---|---|---|
| Verdict | Overvalued | Undervalued |
| Price | $42.62 | $83.48 |
| Intrinsic value | $20.28 | $113.90 |
| Margin of safety | -110% | +27% |
| Market cap | $49.7B | $33.9B |
| Revenue growth, 5 years | 0.8% | 7.2% |
| Operating margin | 19.2% | 37.4% |
| Net margin | 2.9% | 26.2% |
| Return on equity | 6.7% | 57.1% |
| Debt to equity | 2.13 | 2.80 |
| P/E | 100.3x | 14.2x |
| Forward P/E | 13.7x | 13.2x |
| P/B | 6.2x | 10.3x |
| Dividend yield | — | 2.5% |